Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
50242-0051-21 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov. 26, 1997 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sept. 18, 2020 In Use
50242-0132-01 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 10, 2017 In Use
50242-0132-10 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 3, 2019 In Use
50242-0917-01 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 18, 2016 In Use
50242-0917-86 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Aug. 11, 2016 In Use
16714-0001-01 16714-0001 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 22, 2021 In Use
43598-0859-11 43598-0859 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 6, 2019 In Use
43598-0948-11 43598-0948 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 1, 2020 In Use
51662-1483-01 51662-1483 SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT 500.0 mg/4mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Dec. 14, 2019 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
68001-0480-22 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68001-0480-35 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68083-0381-01 68083-0381 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0169-22 70700-0169 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
42658-0019-01 42658-0019 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 20, 2020 In Use
43598-0389-57 43598-0389 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous April 22, 2019 In Use
47335-0323-40 47335-0323 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0895-40 47335-0895 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0939-40 47335-0939 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
49315-0007-10 49315-0007 Arsenic trioxide Arsenic trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Sept. 3, 2019 In Use
49315-0008-03 49315-0008 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
49315-0009-07 49315-0009 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
50742-0430-01 50742-0430 decitabine DECITABINE 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sept. 25, 2019 In Use
55150-0386-01 55150-0386 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 3, 2020 In Use
60505-6132-06 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 4, 2017 In Use
60505-6132-07 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 4, 2017 In Use
60505-6132-08 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 5, 2020 In Use
63323-0825-20 63323-0825 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 2, 2019 In Use
63759-3028-01 63759-3028 gemcitabine GEMCITABINE 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
63759-3029-01 63759-3029 gemcitabine GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
72485-0213-15 72485-0213 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Sept. 4, 2020 In Use
68083-0382-01 68083-0382 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0170-22 70700-0170 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
68083-0259-01 68083-0259 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 10, 2019 In Use
68001-0389-36 68001-0389 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0390-77 68001-0390 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0391-79 68001-0391 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
67184-0501-01 67184-0501 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
67184-0502-01 67184-0502 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
68001-0468-36 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
68001-0468-37 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
65219-0200-05 65219-0200 Temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Nov. 20, 2020 In Use
68083-0202-01 68083-0202 Temsirolimus Injection Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug. 26, 2019 In Use
16729-0295-12 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Oct. 3, 2017 In Use
16729-0295-31 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use
16729-0295-33 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use

Found 10,000 results in 9 millisecondsExport these results